Timothy Romberger - 22 Jun 2021 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Role
Director
Signature
/s/ Andrew Gengos, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
22 Jun 2021
Net transactions value
$0
Form type
4
Filing time
24 Jun 2021, 20:52:42 UTC
Previous filing
17 Jun 2021
Next filing
24 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYT Common Stock Conversion of derivative security +79,060 +27% 369,448 22 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYT Series A Convertible Preferred Stock Conversion of derivative security -69,503 -100% 0 22 Jun 2021 Common Stock 20,390 Direct F1
transaction CYT Series B Convertible Preferred Stock Conversion of derivative security -200,000 -100% 0 22 Jun 2021 Common Stock 58,670 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date.